Palvella to Present Phase 3 QTORIN Trial Results for Lymphatic Malformations
Palvella to present Phase 3 SELVA trial results for QTORIN gel treating lymphatic malformations on February 24, 2026, with data release at 6:30 a.m. ET.
PVLAPhase 3 clinical trialFDA approval